MedTrace Logo

Body Weight, Sleep, and Heart Health

NCT03388788 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2026-05-18

Study results available
· View outcomes & findings →

Summary

A multidisciplinary investigation examining the circadian mechanisms regulating cardiovascular (CV) risk, with an additional focus on obesity. Specifically, in a valid circadian protocol, the investigators aim to study resting cardiovascular risk markers and the reactivity of circadian rhythms in these risk markers to standardized stressors. It is intended to compare results in lean and obese individuals to determine if there are specific risks across the circadian cycle specific to obesity. Furthermore, using an exploratory approach, the investigators propose to explore impairment in pre/post synaptic function in the cardiac left ventricle.

Conditions

  • Cardiovascular Risk Factor
  • Circadian Dysregulation
  • Obesity

Interventions

COMBINATION_PRODUCT

Positron Emission Tomography (PET) scanning of cardiac function at 3 time points across the 24 hour circadian cycle

Drugs are used for as part of physiological monitoring and not as interventions, including imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, and 11C-CGP12177).

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • National Center for Advancing Translational Sciences (NCATS)

    collaborator NIH

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Steven A Shea, PhD · Oregon Institute of Occupational Health Sciences

  • Jeanne M Link, PhD · OHSU Center for Radiochemistry Research

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2024-09-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03388788 on ClinicalTrials.gov